Eli Lilly (LLY) announced that the highest approved doses of Zepbound-12.5 mg and 15 mg-will soon be available in single-dose vials for $499 per month through LillyDirect’s Self Pay Pharmacy Solutions and the Zepbound Self Pay Journey Program. Health care providers can begin prescribing the 12.5 mg and 15 mg vials on July 7, and shipments to patients will begin in early August. With the addition of these doses, every strength of Zepbound vial will be available for $499/month or less to any eligible adult with obesity and a valid prescription, regardless of insurance.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- Jefferies sees Akero, Scholar Rock as ‘promising’ takeover targets
- Eli Lilly & Co’s Innovative Pipeline and Growth Potential Drive Buy Rating
- UBS Reiterates Buy Rating on Eli Lilly Stock (LLY) and Lauds Pricing Strategy
- Senators to propose ban on drug ads to consumers, WSJ reports
- RFK Jr. names eight members to vaccine panel, WSJ reports
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue